KLF4 suppresses estrogen-dependent breast cancer growth by inhibiting the transcriptional activity of ERα

K. Akaogi, Y. Nakajima, Ichiaki Ito, S. Kawasaki, S. H. Oie, A. Murayama, K. Kimura, J. Yanagisawa

Research output: Contribution to journalArticle

72 Scopus citations

Abstract

Kruppel-like factor 4 (KLF4) is a transcription factor that participates in both tumor suppression and oncogenesis. To determine the association of KLF4 with tumorigenesis, we integrated data assembled in the Oncomine database and discovered a decrease in KLF4 gene transcripts in breast cancers. Further analysis of the database also showed a correlation between KLF4 expression and estrogen receptor-α (ERα) positivity. Knockdown of KLF4 in MCF-7 cells elevated the growth rate of these cells in the presence of estrogen. Therefore, we examined the interaction between KLF4 and ERα, and found that KLF4 bound to the DNA-binding region of ERα. KLF4 thus inhibits the binding of ERα to estrogen response elements in promoter regions, resulting in a reduction in ERα target gene transcription. Earlier studies have reported that KLF4 is transcriptionally activated by p53 following DNA damage. We also showed that activation of p53 decreased the transcriptional activity of ERα by elevating KLF4 expression. Our studies discovered a novel molecular network between p53, KLF4 and ERα. As both p53 and ERα are involved in cell growth and apoptosis, these results may explain why KLF4 possesses both tumor suppressive and oncogenic functions in breast cancers.

Original languageEnglish (US)
Pages (from-to)2894-2902
Number of pages9
JournalOncogene
Volume28
Issue number32
DOIs
StatePublished - Aug 13 2009
Externally publishedYes

    Fingerprint

Keywords

  • Breast cancer
  • Estrogen receptor
  • KLF4
  • p53

ASJC Scopus subject areas

  • Molecular Biology
  • Genetics
  • Cancer Research

Cite this

Akaogi, K., Nakajima, Y., Ito, I., Kawasaki, S., Oie, S. H., Murayama, A., Kimura, K., & Yanagisawa, J. (2009). KLF4 suppresses estrogen-dependent breast cancer growth by inhibiting the transcriptional activity of ERα. Oncogene, 28(32), 2894-2902. https://doi.org/10.1038/onc.2009.151